These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16462975)

  • 21. Is a statin as part of a polypill the answer?
    Robinson JG
    Curr Atheroscler Rep; 2009 Jan; 11(1):15-22. PubMed ID: 19080723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Polypill at 20 - What Have We Learned?
    Wang TJ
    N Engl J Med; 2022 Sep; 387(11):1034-1036. PubMed ID: 36018010
    [No Abstract]   [Full Text] [Related]  

  • 23. A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease.
    Al-Abdouh A; Mhanna M; Jabri A; Ahmed T; Altibi AM; Ghanem F; Alhuneafat L; Mostafa MR; Abusnina W; Dewaswala N; Bhopalwala H; Kundu A; Michos ED
    Am J Ther; 2024 Mar-Apr 01; 31(2):e193-e195. PubMed ID: 36857708
    [No Abstract]   [Full Text] [Related]  

  • 24. Four in one polypill halves predicted cardiovascular risk, international study shows.
    Mayor S
    BMJ; 2011 May; 342():d3355. PubMed ID: 21622499
    [No Abstract]   [Full Text] [Related]  

  • 25. Polypill for cardiovascular disease prevention.
    Dalton AR
    JAMA; 2013 Aug; 310(7):749. PubMed ID: 23989135
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
    Fletcher GF; Bufalino V; Costa F; Goldstein LB; Jones D; Smaha L; Smith SC; Stone N
    Am J Cardiol; 2007 Mar; 99(6C):1E-35E. PubMed ID: 17378996
    [No Abstract]   [Full Text] [Related]  

  • 27. Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations-A Social Epidemiology Counterargument.
    Cainzos-Achirica M; Bilal U
    Am J Med; 2020 Oct; 133(10):e541-e543. PubMed ID: 32442515
    [No Abstract]   [Full Text] [Related]  

  • 28. Polypill for cardiovascular disease prevention--reply.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
    [No Abstract]   [Full Text] [Related]  

  • 29. The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era.
    Muñoz D; Wang TJ
    Circulation; 2019 Nov; 140(22):1776-1778. PubMed ID: 31765254
    [No Abstract]   [Full Text] [Related]  

  • 30. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed dose combination therapy and CVD protection: "a need of the hour".
    Chopra HK
    Indian Heart J; 2009; 61(4):316-21. PubMed ID: 20635732
    [No Abstract]   [Full Text] [Related]  

  • 32. One Pill for Everyone? Twenty Years of Polypill for Cardiovascular Disease.
    Tran RJC
    Am J Cardiol; 2023 Sep; 203():493-495. PubMed ID: 37500317
    [No Abstract]   [Full Text] [Related]  

  • 33. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 35. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 36. The Indian Polycap Study (TIPS).
    Urquhart J
    Lancet; 2009 Sep; 374(9692):781-2; author reply 782. PubMed ID: 19733773
    [No Abstract]   [Full Text] [Related]  

  • 37. A polypill for secondary prevention: time to move from intellectual debate to action.
    Fuster V; Sanz G
    Nat Clin Pract Cardiovasc Med; 2007 Apr; 4(4):173. PubMed ID: 17380163
    [No Abstract]   [Full Text] [Related]  

  • 38. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart health and diet.
    Colt E
    J Am Diet Assoc; 2008 Jan; 108(1):34. PubMed ID: 18155985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.